Luteolin suppresses oral carcinoma 3 (OC3) cell growth and migration via modulating polo-like kinase 1 (PLK1) expression and cellular energy metabolism.

Pengfei Gao; Wentao Zhang; Yujie Lin; Ruijie LU; Zijian Lou; Gang LU; Ruolang Pan; Yunfang Chen

Return

Luteolin suppresses oral carcinoma 3 (OC3) cell growth and migration via modulating polo-like kinase 1 (PLK1) expression and cellular energy metabolism.

Author: Pengfei GAO ¹ ; Wentao ZHANG ¹ ; Yujie LIN ² ; Ruijie LU ² ; Zijian LOU ² ; Gang LU ³ ; Ruolang PAN ⁴ ; Yunfang CHEN ⁵
Author Information

1. Center for Plastic & Reconstructive Surgery, Department of Stomatology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China.
2. The Second Clinical Medical College, Wenzhou Medical University, Wenzhou 325035, China.
3. Key Laboratory of Cell-Based Drug and Applied Technology Development in Zhejiang Province, Hangzhou 311122, China.
4. Key Laboratory of Cell-Based Drug and Applied Technology Development in Zhejiang Province, Hangzhou 311122, China. panrl@zju.edu.cn.
5. Center for Plastic & Reconstructive Surgery, Department of Stomatology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China. panrl@zju.edu.cn, chenyunfang@hmc.edu.cn.
Publication Type:Journal Article
MeSH: Humans; Mouth Neoplasms/pathology*; Carcinoma, Squamous Cell/metabolism*; Luteolin/therapeutic use*; Squamous Cell Carcinoma of Head and Neck/drug therapy*; Head and Neck Neoplasms/drug therapy*; Cell Line, Tumor
From: Journal of Zhejiang University. Science. B 2023;24(12):1151-1158
CountryChina
Language:English
Abstract: Oral squamous cell carcinoma (OSCC) is a prevalent malignant tumor affecting the head and neck region (Leemans et al., 2018). It is often diagnosed at a later stage, leading to a poor prognosis (Muzaffar et al., 2021; Li et al., 2023). Despite advances in OSCC treatment, the overall 5-year survival rate of OSCC patients remains alarmingly low, falling below 50% (Jehn et al., 2019; Johnson et al., 2020). According to statistics, only 50% of patients with oral cancer can be treated with surgery. Once discovered, it is more frequently at an advanced stage. In addition, owing to the aggressively invasive and metastatic characteristics of OSCC, most patients die within one year of diagnosis. Hence, the pursuit of novel therapeutic drugs and treatments to improve the response of oral cancer to medication, along with a deeper understanding of their effects, remains crucial objectives in oral cancer research (Johnson et al., 2020; Bhat et al., 2021; Chen et al., 2023; Ruffin et al., 2023).